Suppr超能文献

抗高血压药物与新发糖尿病:一项回顾性纵向队列研究。

Antihypertensive drugs and new-onset diabetes: a retrospective longitudinal cohort study.

作者信息

Jong Gwo-Ping, Chang Mu-Hsin, Tien Liyun, Li Shu-Yi, Liou Yi-Sheng, Lung Chi-Hsuan, Ma Tsochiang

机构信息

Division of Internal Cardiology, Armed Forces Taichung General Hospital, Central Taiwan University of Science and Technology, Taichung, Taiwan, ROC.

出版信息

Cardiovasc Ther. 2009 Fall;27(3):159-63. doi: 10.1111/j.1755-5922.2009.00092.x.

Abstract

Antihypertensive drugs have been linked to new-onset diabetes (NOD); however, data on the effect of these drugs on the development of NOD in hypertensive patients has not been well determined. We aimed to investigate the association between antihypertensive drugs and NOD. This was a retrospective cohort study performed using data from claim forms provided to the central region branch of the Bureau of National Health Insurance in Taiwan from January 2002 to December 2007. Prescriptions for antihypertensive drugs before the index date were retrieved from a prescription database. We estimated the odds ratios (ORs) of NOD associated with antihypertensive drug use; nondiabetic subjects served as the reference group. A total of 4233 NOD cases were identified in 24,688 hypertensive patients during the study period. The risk of NOD after adjusting for sex and age was higher among users of diuretics (OR = 1.10, 95% confidence interval [CI]= 1.01-1.20), beta-blockers (BBS; OR = 1.12, 95% CI = 1.04-1.21), and calcium channel blockers (CCBs; OR = 1.10, 95% CI = 1.02-1.18) than among nonusers. Patients who take angiotensin-converting enzyme (ACE) inhibitors (OR = 0.92, 95% CI = 0.84-1.00), angiotensin receptor blockers (ARB; OR = 0.90, 95% CI = 0.81-0.98), or alpha-blockers (OR = 0.88, 95% CI = 0.80-0.98) are at a lower risk of developing NOD than nonusers. Vasodilators were not associated with the risk of NOD. The results of this study suggest that hypertensive patients who take ACE inhibitors, ARBs, or alpha-blockers are at a lower risk of NOD. Diuretics, BBs, and CCBs were associated with a significant increase in the risk of NOD.

摘要

抗高血压药物与新发糖尿病(NOD)有关;然而,这些药物对高血压患者发生NOD的影响的数据尚未得到充分确定。我们旨在研究抗高血压药物与NOD之间的关联。这是一项回顾性队列研究,使用了2002年1月至2007年12月提供给台湾国民健康保险局中部地区分支机构的理赔表单数据。从处方数据库中检索索引日期之前的抗高血压药物处方。我们估计了与使用抗高血压药物相关的NOD的比值比(OR);非糖尿病患者作为参照组。在研究期间,24,688名高血压患者中总共确定了4233例NOD病例。在调整性别和年龄后,利尿剂使用者(OR = 1.10,95%置信区间[CI]= 1.01 - 1.20)、β受体阻滞剂(BBs;OR = 1.12,95% CI = 1.04 - 1.21)和钙通道阻滞剂(CCBs;OR = 1.10,95% CI = 1.02 - 1.18)发生NOD的风险高于未使用者。服用血管紧张素转换酶(ACE)抑制剂(OR = 0.92,95% CI = 0.84 - 1.00)、血管紧张素受体阻滞剂(ARB;OR = 0.90,95% CI = 0.81 - 0.98)或α受体阻滞剂(OR = 0.88,95% CI = 0.80 - 0.98)的患者发生NOD的风险低于未使用者。血管扩张剂与NOD风险无关。这项研究的结果表明,服用ACE抑制剂、ARB或α受体阻滞剂的高血压患者发生NOD的风险较低。利尿剂、BBs和CCBs与NOD风险的显著增加有关。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验